Micromedic – a Unique Cluster of Cancer Diagnostic Solutions     News
  Micromedic Technologies Ltd. specializes in the development and commercialization of innovative in vitro cancer diagnostic products and solutions. Our portfolio includes state-of-the-art technologies involving gene expression, biomarker and histochemical assays for early cancer detection and personalized medicine.
Micromedic offers proprietary diagnostic solutions for multiple cancer diagnostic applications, providing practical answers to real unmet needs.

Micromedic is a public company traded on the Tel Aviv Stock Exchange (TASE: MCTC).

Micromedic Obtains EU CE Mark for CellDetect® Non-Invasive Test for Detecting Recurrence of Bladder Cancer

Micromedic Reports Successful Clinical Study Results for Monitoring Bladder Cancer Recurrence

Micromedic Reports Successful Interim Results from Bladder Cancer Clinical Study

Micromedic identifies new genetic markers to predict risk of developing BRONJ

Micromedic reports success in clinical pilot of its Cervical Cancer diagnostic product in a central hospital in Beijing

Zetiq has signed a memorandum of understanding for collaboration in India

Successful interim results in a trial of a test for recurrence of bladder cancer cells in urine specimens

Zetiq receives patent approval in Japan for its cell staining technology

Marketing approval for Zetiq's CellDetect in China

BioLight will invest 4 million NIS for additional 5% of Micromedic

© Micromedic Technologies Ltd. site mapcontact
Site by Site2goal | Design Studio Michal Lehavi